摘要
为探讨表皮生长因子受体(EGFR)单抗联合FOLFOX方案治疗晚期转移性结直肠癌(mCRC)的有效性及安全性,选择2015年9月至2018年9月我院收治的148例mCRC患者作为研究对象,随机数字表法分为观察组和对照组,各74例。对照组接受FOLFOX方案化疗,观察组在对照组治疗基础上联合应用EGFR单抗(尼妥珠单抗注射液)治疗。比较2组患者临床疗效及不良反应。结果显示,观察组疾病总缓解率(ORR)为31.08%(23/74),疾病控制率(DCR)为82.43%(61/74);对照组ORR为22.97%(17/74),DCR为59.46%(44/74)。观察组ORR和DCR均明显高于对照组,P<0.05。2组患者恶心呕吐、神经毒性、腹泻、肝肾功能损伤、白细胞减少、血小板减少等不良反应发生率比较,差异均无统计学意义,P>0.05。结果表明,FOLFOX方案治疗晚期转移性结直肠癌的同时,联合应用EGFR单抗治疗,可提高疗效,而且不增加不良反应,值得临床推广。
This study was to explore the effectiveness and safety of late metastatic colorectal carcinoma(mCRC)treated with FOLFOX schema plus EGFR monoclonal antibody,enrolled 148 mCRC patients treated in author’s hospital(2015-09-2018-09)and randomly divided them into observation group(74 cases,received FOLFOX schema plus EGFR monoclonal antibody)and control group(74 cases,alone FOLFOX schema);then compared patient’s effect and their untoward reaction between the two groups.As results,in ORR(short for overall remission rate)and in DCR(short for disease control rate)observation group was all significantly higher than control group[31.08%(23/74)vs 22.97%(17/45),82.43%(61/74)vs 59.46%(44/74),all,P<0.05];in the incidence of untoward reactions such as nausea&vomitting,neurotoxicity,diarrhea,liver and kidney function injuried,leukopenia,and thrombocytopenia,etc,there was no significant difference between the two groups(P>0.05).Results show that above combined therapy can enhance effect,and not increase untoward reaction incidence,it is worthy to be popularized clinically.
作者
张颢
ZHANG Hao(Pharmacy Division,the First Affiliated Hospital to Henan University,Kai feng,Henan 475000)
出处
《中国肛肠病杂志》
2020年第2期3-5,共3页
Chinese Journal of Coloproctology
基金
开封市科技发展计划项目(1703014).
